1Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole (femara) versus tamoxifen as first-line therapy forpostmenopausal women with advanced breast cancer: result of a phase Ⅲ study of the international letrozole breast canner group[J]. J Clin Oncol, 2001,19(10): 2596-2606.
2Ellis M J, Coop A, Singgh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for erbB-1-and/or erbB-2-positive, primary breast cancer: evdence from a phase Ⅲ randomized trial[J]. J Clin Oncol, 2001,19(18): 3808-3816.
